Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

The authors conducted a nested case-control study of serum steroid concentrations and risk of benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH over 7 years (n = 708) was defined as receipt of treatment, a report of 2 International Prostate Symptom Score (IPSS) values greater than 14, or 2 increases of 5 or more from baseline IPSS values with at least 1 value greater than or equal to 12. Controls (n = 709) were selected from men who reported no BPH treatment or any IPSS greater than 7. Baseline serum was analyzed for testosterone, estradiol, estrone, 5alpha-androstane-3alpha, 17beta-diol-glucuronide, and sex hormone-binding globulin. Covariate-adjusted odds ratios contrasting the highest quartiles with the lowest quartiles of testosterone, estradiol, and testosterone:17beta-diol-glucuronide ratio were 0.64 (95% confidence interval (CI): 0.43, 0.95; P(trend) = 0.04), 0.72 (95% CI: 0.53, 0.98; P(trend) = 0.09), and 0.64 (95% CI: 0.46, 0.89; P(trend) = 0.004), respectively. Findings did not differ by age, body mass index, time to BPH endpoint, or type of BPH endpoint. High testosterone levels, estradiol levels, and testosterone:17beta-diol-glucuronide ratio are associated with reduced BPH risk, which may reflect decreased activity of 5-alpha-reductase. Genetic or environmental factors that affect the activity of 5-alpha-reductase may be important in the development of symptomatic BPH.

[1]  I. Thompson,et al.  Insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial , 2008, The Prostate.

[2]  I. Thompson,et al.  Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2008, American journal of epidemiology.

[3]  Wen-Jeng Wu,et al.  Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. , 2007, Urology.

[4]  J. Mckinlay,et al.  An investigation of the relationship between sex‐steroid levels and urological symptoms: results from the Boston Area Community Health survey , 2007, BJU international.

[5]  G. Risbridger,et al.  Treating prostate cancer: a rationale for targeting local oestrogens , 2007, Nature Reviews Cancer.

[6]  I. Thompson,et al.  Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2007, The Journal of urology.

[7]  E. Giovannucci,et al.  Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). , 2007, Urology.

[8]  T. Travison,et al.  The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. , 2007, The Journal of clinical endocrinology and metabolism.

[9]  J. Kaufman,et al.  The decline of androgen levels in elderly men and its clinical and therapeutic implications. , 2005, Endocrine reviews.

[10]  G. Ursin,et al.  Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. , 2005, Urologic oncology.

[11]  E. Bergstralh,et al.  Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH , 2005 .

[12]  R. Roberts,et al.  Serum sex hormones and measures of benign prostatic hyperplasia , 2004, The Prostate.

[13]  R. Rodriguez,et al.  Nutritional genomics: the next frontier in the postgenomic era , 2003 .

[14]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[15]  E. Riboli,et al.  Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls , 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[16]  Michael M Lieber,et al.  Journal Review , 2003, International Society of Hair Restoration Surgery.

[17]  T. Habuchi,et al.  Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. , 2003, The Journal of urology.

[18]  G. Miller,et al.  Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. , 2003, Controlled clinical trials.

[19]  F. Orio,et al.  Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines , 2002, Molecular and Cellular Endocrinology.

[20]  K. Cooney,et al.  Relationship of serum sex‐steroid hormones and prostate volume in African American men , 2002, The Prostate.

[21]  Jie Deng,et al.  Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. , 2002, The Journal of urology.

[22]  J. Fraumeni,et al.  Insulin‐like growth factors and risk of benign prostatic hyperplasia † , 2002, The Prostate.

[23]  E. Giovannucci,et al.  Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. , 2002, Urology.

[24]  M. Barry,et al.  Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. , 2001, Journal of clinical epidemiology.

[25]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[26]  R. Kirby,et al.  The natural history of benign prostatic hyperplasia: what have we learned in the last decade? , 2000, Urology.

[27]  N. Makridakis,et al.  Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. , 2000, Pharmacogenetics.

[28]  B. Djavan,et al.  Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. , 2000, Urology.

[29]  E. Rimm,et al.  Plasma steroid hormones, surgery for benign prostatic hyperplasia, and severe lower urinary tract symptoms , 1999, Prostate Cancer and Prostatic Diseases.

[30]  L. Lipworth,et al.  Serum steroids in relation to benign prostatic hyperplasia. , 1997, Oncology.

[31]  P. Taylor,et al.  Effects of dietary fat and fiber on plasma and urine androgens and estrogens in men: a controlled feeding study. , 1996, The American journal of clinical nutrition.

[32]  E. Metter,et al.  Longitudinal evaluation of serum androgen levels in men with and without prostate cancer , 1995, The Prostate.

[33]  H. Yamanaka,et al.  Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration. , 1995, Scandinavian journal of urology and nephrology.

[34]  F. Grodstein,et al.  A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia , 1995, The Prostate.

[35]  E. Rimm,et al.  Obesity and benign prostatic hyperplasia. , 1994, American journal of epidemiology.

[36]  D. de Lorenzo,et al.  Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. , 1994, The Journal of clinical endocrinology and metabolism.

[37]  R. Horton,et al.  Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth factor-I. , 1993, Endocrinology.

[38]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[39]  K. Carlström,et al.  Testicular and adrenocortical function in healthy men and in men with benign prostatic hyperplasia , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[40]  R. Hayes,et al.  Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. , 1991, Cancer research.

[41]  J. Geller.  Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. , 1990, The Journal of clinical endocrinology and metabolism.

[42]  B. Hulka,et al.  Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls , 1988, The Prostate.

[43]  A. Bélanger,et al.  Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia. , 1988, The Prostate.

[44]  H. Adlercreutz,et al.  Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. , 1983, The Prostate.

[45]  A. Schindler,et al.  Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate. , 1982, Journal of steroid biochemistry.

[46]  T. Bäckström,et al.  Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. , 1982, Journal of steroid biochemistry.

[47]  N. Breslow,et al.  Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. , 1981 .

[48]  E. Ortega,et al.  Plasma steroid and protein hormone concentrations in patients with benign prostatic hypertrophy and in normal men , 1979, Experientia.

[49]  M. Krieg,et al.  Hormone blood levels and their inter-relationships in normal men and men with benign prostatic hyperplasia (BPH). , 1979, Acta endocrinologica.

[50]  G. Hammond,et al.  SERUM STEROIDS IN NORMAL MALES AND PATIENTS WITH PROSTATIC DISEASES , 1978, Clinical endocrinology.

[51]  A. Vermeulen,et al.  Androgens in patients with benign prostatic hyperplasia before and after prostatectomy. , 1976, The Journal of clinical endocrinology and metabolism.

[52]  C. Lieber,et al.  Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. , 1976, The New England journal of medicine.

[53]  R. Horton,et al.  Altered blood androgens in elderly men with prostate hyperplasia. , 1975, The Journal of clinical endocrinology and metabolism.

[54]  W. Bremner,et al.  Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist. , 2005, The Journal of clinical endocrinology and metabolism.

[55]  M. Uygur,et al.  Serum concentrations of sex hormones in men with severe lower urinary tract symptoms and benign prostatic hyperplasia , 2004, International Urology and Nephrology.

[56]  C. Weinberg,et al.  A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH , 2004, The Pharmacogenomics Journal.

[57]  C. Foster,et al.  Pathology of benign prostatic hyperplasia , 2000, The Prostate. Supplement.

[58]  M. Hill,et al.  Analysis of relations between serum levels of epitestosterone, estradiol, testosterone, IGF-1 and prostatic specific antigen in men with benign prostatic hyperplasia and carcinoma of the prostate. , 2000, Physiological research.

[59]  N. Breslow,et al.  The analysis of case-control studies , 1980 .

[60]  K. Carlström,et al.  Serum hormone levels in benign prostatic hyperplasia. , 1978, Scandinavian journal of urology and nephrology.